BIAsp 30

also known as NovoMix 30-pen

Developed for: type 1 diabetes mellitus · type 2 diabetes mellitus
Investigated by: Novo Nordisk A/S · Tehran University of Medical Sciences · University of Aarhus

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 41 trial
Phase 4	NCT01889095	Jul → Aug 2011	type 2 diabetes mellitus	Tehran University of Medical Sciences	Completed	No outcome recorded
Phase not applicable1 trial
—	NCT00283218	Jan → Aug 2006	type 1 diabetes mellitus	University of Aarhus	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT03018665 Comparator	Feb 2017 → Dec 2021	type 2 diabetes mellitus	The First Hospital of Jilin University	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	BIAsp30	“The profiles will be derived over a 12-hour period after subcutaneous injection in the abdominal region with a single dose of IAsp, BIAsp 30, BIAsp 50 or BIAsp 70 at a test meal.” NCT00283218 ↗ 2 NCT03018665 ↗ NCT01889095 ↗
Known as	NovoMix 30-pen	“The starting dose of BIAsp 30 (NovoMix® 30-pen, NovoNordisk) was 0.2-0.6 unit/kg per day in 2 divided doses according to level of glycemia in the intervention group.” NCT01889095 ↗
Route	Subcutaneous	“subcutaneous injection” NCT03018665 ↗